• Mahesh Mamilla, Nikhita Yadav Maddeti, Pawan Kumar Thada, Iman Mahamoud, Sarosh Sarwar, Madeeha Subhan Waleed, Shikha Yadav, Manaal Mustansir, Anuradha Raut, George Yatzkan, and Javier Perez-Fernandez.
• From the Division of Research and Academic Affairs, Larkin Community Hospital, South Miami, and the Pulmonary Medicine Fellowship Training Program and the Pulmonary and Critical Care Fellowship Training Program, Larkin University, Miami, Florida.
• South. Med. J. 2022 Aug 1; 115 (8): 611-615.

AbstractOf the patients with asthma, 20% to 25% progress to severe symptoms, resulting in poor quality of life and increased episodes of exacerbation. There is a broad range of drugs used for asthma; the most used medications for severe asthma are inhaled glucocorticoids with or without long-acting β-agonists. Systemic glucocorticoids and other treatments as add-on therapies are also given as needed. Chronic glucocorticoid use is associated with numerous adverse effects, including diabetes mellitus, osteoporosis, anxiety, depression, and cataracts. The occurrence of these side effects has been reduced because of the emergence of new biological therapies. One such treatment is dupilumab, which helps in the reduction of type 2 inflammation involved in the pathophysiology of asthma. We conducted a literature review to assess the efficacy, adverse effects, and pharmacological benefits of dupilumab in glucocorticoid-dependent asthma. In most randomized controlled trials, dupilumab has shown significant efficacy and safety profile in patients with severe asthma with corticosteroid dependence. Associated adverse effects such as injection site reaction and transient eosinophilia have been reported. Our review of the literature indicates that dupilumab has proven to improve lung function, reduce the rate of asthma exacerbations, and reduce the use of corticosteroids.

14 keywords...

hide…